Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company’s investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age. Dengue is a mosquito-borne virus endemic in more than 125 countries, including the U.S. t…


– 출처 : https://www.newswire.co.kr/newsRead.php?no=956350&sourceType=rss

함께 보면 좋은 콘텐츠